Posts Tagged ‘antidepressants’

Judge Agrees Prozac Turned Teen into Murderer

Monday, October 3rd, 2011

Antidepressant Caused a Stimulant-like Syndrome Leading to Manic-like Behavior, Suicidality and Violence

PR Newswire—October 3, 2011

Judge Robert Heinrich listened to expert psychiatric testimony for the defense by Peter Breggin, MD and issued his opinion regarding the sixteen-year-old who stabbed his friend to death.

The judge stated, “His basic normalcy now further confirms he no longer poses a risk of violence to anyone and that his mental deterioration and resulting violence would not have taken place without exposure to Prozac.” Consistent with Dr. Breggin’s testimony, the judge observed, “He has none of the characteristics of a perpetrator of violence. The prospects for rehabilitation are good.”

This is the first criminal case in North America where a judge has specifically found that an antidepressant was the cause of a murder.

The case involved a high school student with no violence who abruptly stabbed one of his friends to death at home with a single wound to the chest. The boy had been taking Prozac for three months, during which his behavior deteriorated.

Starting approximately 2005 to the present, the FDA required official drug labels to include information about dangers under the section titled WARNINGS-Clinical Worsening and Suicide Risk. The list of adverse effects—”anxiety, agitation, panic attacks,insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania”—is a prescription for violence. Canadian drug regulatory agency,  Health Canada, also warns about these side effects.

Dr. Breggin testified the boy’s symptoms were consistent with a Prozac (fluoxetine) Induced Mood Disorder with Manic Features and he would not have committed the violence if he had not been given the antidepressant. He brought numerous independent scientific studies to court confirming his testimony.

The hearing determined whether or not the now 17 year old should be sentenced as a minor, limiting jail time. The prosecution wanted him tried as an adult. On October 4, 2011 final sentencing will occur. The judge’s decision represents an enormous step forward in recognizing the newer antidepressants can cause violence.

« Return to news items


Share

The Drugging of America

Thursday, September 29th, 2011

The Journal – September 29, 2011

by Barry Evans

The theory that psychological problems are mainly caused by a chemical imbalance in the brain can be traced back 60 years, when French researchers accidentally discovered that Thorazine (chlorpromazine) dramatically improved the emotional behavior of institutionalized mental patients. Within a few years, the anti-psychotic properties of Thorazine and related drugs led to the trend in this country to reintegrate into society people who had previously been confined to mental hospitals (“deinstitutionalization”).

Prozac advertisement

Today, the “chemical imbalance” revolution is almost complete, as one in 10 Americans over the age of 6 take antidepressants. As Marcia Angell, former editor-in-chief of The New England Journal of Medicine, wrote in a controversial two-part essay in The New York Review of Books (June 23 and June 30, 2011), the pharmaceutical solution to psychological disorders has now become the norm, as more and more health professionals accept the theory that mental illness, including depression and anxiety, is essentially caused by a chemical imbalance in the brain.

The wholesale acceptance of this theory, by both the medical profession and the public, came with the introduction of Prozac (fluoxetine) in 1987. While Thorazine was thought to correct a deficiency of dopamine, Prozac was marketed as an SSRI (selective serotonin reuptake inhibitor), designed to compensate for a presumed deficit of the neurotransmitter serotonin. (SSRIs block neurons from re-absorbing serotonin, leaving more of it available to activate adjacent neurons.) Because SSRIs alleviate depression, researchers speculated that depression was caused by too little serotonin in the brain.

Maybe. Or maybe not. Angell argues that by the same logic “one could argue that fevers are caused by too little aspirin.” Perhaps SSRIs do something quite unrelated to neurotransmitters, and depression is unrelated to serotonin levels.

Whether the “chemical imbalance” theory is true or not, the real question is, Do antidepressants work better than placebos? Psychologist Irving Kirsch, one of the authors reviewed by Angell, used the Freedom of Information Act to obtain drug companies’ records of their negative studies from the FDA. Unlike the positive results, negative results are normally not published. (Incredibly to this writer, negative results are considered proprietary and therefore confidential.) Taking both positive and negative results into consideration, Kirsch discovered that six popular drugs — Prozac, Paxil, Zoloft, Celexa, Serzone, and Effexor — scored unimpressively when compared with placebos. Yet, as Angell writes, “because the positive studies were extensively publicized, while the negative ones were hidden, the public and the medical profession came to believe that these drugs were highly effective antidepressants.” It gets more surreal. When depressed patients were prescribed drugs such as opiates, sedatives, stimulants and even herbal remedies, Kirsch and others found their symptoms were relieved to about the same degree as with SSRI-type antidepressants.

Angell’s essay was, as I say, controversial. One of the more curious responses, published as an opinion piece in the New York Times on July 9, came from Dr. Peter Kramer, author of the 1993 best-seller Listening to Prozac. This book-length endorsement of the drug (which predicted a Brave New World-style “cosmetic psychopharmacology” future for us all) probably did more than anything else to turn Americans on to SSRIs. In his Times piece, Kramer largely sidestepped the alarming questions posed by Angell and the three books she reviewed. Instead, he focused on the difficulties of distinguishing the effects of placebos from those of real drugs. And as he had done in his book, he relied largely on unconvincing anecdotal evidence to make his case.

What we do know about placebos is that they’re not dangerous. However, even as increasing numbers of adults and children take powerful psychoactive drugs (because more of us are suffering?), researchers still have no clear handle on their potentially damaging long-term effects.

Barry Evans  gets depressed just thinking about antidepressants.

http://www.northcoastjournal.com/outdoors/2011/09/29/drugging-america/

« Return to news items


Share

Are Psychiatric Medications Making Us Sicker?

Monday, September 19th, 2011

The Chronicle of Higher Education – September 18, 2011
by By John Horgan

American psychiatry, in collusion with the pharmaceutical industry, is perpetrating what may be the biggest case of iatrogenesis—harmful medical treatment—in history.Dave Plunkert for The Chronicle Review

Three years ago, I was reminded in dramatic fashion of the chasm between psychiatry and more-effective branches of medicine. My 14-year-old son, Mac, while playing lacrosse, emerged from a collision with his right arm askew. I drove him to a local hospital, where an orthopedic surgeon on duty immediately diagnosed the injury: dislocated elbow. He gave Mac an oral and local anesthetic and put him in a portable X-ray machine that showed Mac’s elbow joint on a screen, in real time. Watching the screen, the doctor quickly snapped Mac’s elbow back into place.

Overcome with gratitude to the doctor, I was leading my groggy son out of the hospital when my cellphone rang. An old friend, whom I’ll call Phil, was on the line. He was in the psychiatric ward of a New York hospital, to which his 16-year-old son had been committed. The boy, who was taking antidepressants for depression, had threatened to commit suicide, not for the first time. Thedoctors were recommending electroconvulsive therapy, or ECT.

Knowing that I had written about shock therapy and other psychiatric treatments, Phil asked my opinion. The fact that Phil had called me, a mere journalist, for advice in such a dire situation spoke volumes about the troubles of modern psychiatry.

I first took a close look at treatments for mental illness 15 years ago while researching an article for Scientific American. At the time, sales of a new class of antidepressants, selective serotonin reuptake inhibitors, or SSRI’s, were booming. The first SSRI, Prozac, had quickly become the most widely prescribed drug in the world. Many psychiatrists, notably Peter D. Kramer, author of the best seller Listening to Prozac, touted SSRI’s as a revolutionary advance in the treatment of mental illness. Prozac, Kramer said in a phrase that I hope now haunts him, could make patients “better than well.”

Clinical trials told a different story. SSRI’s are no more effective than two older classes of antidepressants, tricyclics and monoamine oxidase inhibitors. What was even more surprising to me—given the rave reviews Prozac had received from Kramer and others—was that antidepressants as a whole were not more effective than so-called talking cures, whether cognitive behavioral therapy or even old-fashioned Freudian psychoanalysis. According to some investigators, treatments for depression and other common ailments work—if they do work—by harnessing the placebo effect, the tendency of a patient’s expectation of improvement to become self-fulfilling. I titled my article “Why Freud Isn’t Dead.” Far from defending psychoanalysis, my point was that psychiatry has made disturbingly little progress since the heyday of Freudian theory.

In retrospect, my critique of modern psychiatry was probably too mild. According to Anatomy of an Epidemic (Crown Publishers, 2010), by the journalist Robert Whitaker, psychiatry has not only failed to progress but may now be harming many of those it purports to help. Anatomy of an Epidemic has been ignored by most major media. I learned about it only after Marcia Angell, former editor of The New England Journal of Medicine and now a lecturer on public health at Harvard, reviewed the book in The New York Review of Books in June. If Whitaker is right, American psychiatry, in collusion with the pharmaceutical industry, is perpetrating what may be the biggest case of iatrogenesis—harmful medical treatment—in history.

As recently as the 1950s, Whitaker contends, the four major mental disorders—depression, anxiety disorder, bipolar disorder, and schizophrenia—often manifested as episodic and “self limiting”; that is, most people simply got better over time. Severe, chronic mental illness was viewed as relatively rare. But over the past few decades the proportion of Americans diagnosed with mental illness has skyrocketed. Since 1987, the percentage of the population receiving federal disability payments for mental illness has more than doubled; among children under the age of 18, the percentage has grown by a factor of 35.

Between 1985 and 2008, sales of antidepressants and antipsychotics multiplied almost fiftyfold, to $24.2-billion.

This epidemic has coincided, paradoxically, with a surge in prescriptions for psychiatric drugs. Between 1985 and 2008, sales of antidepressants and antipsychotics multiplied almost fiftyfold, to $24.2-billion. Prescriptions for bipolar disorder and anxiety have also swelled. One in eight Americans, including children and even toddlers, is now taking a psychotropic medication. Whitaker acknowledges that antidepressants and other psychiatric medications often provide short-term relief, which explains why so many physicians and patients believe so fervently in the drugs’ benefits. But over time, Whitaker argues, drugs make many patients sicker than they would have been if they had never been medicated.

Whitaker compiles anecdotal and clinical evidence that when patients stop taking SSRI’s, they often experience depression more severe than what drove them to seek treatment. A multination report by the World Health Organization in 1998 associated long-term antidepressant usage with a higher rather than a lower risk of long-term depression. SSRI’s cause a wide range of side effects, including insomnia, sexual dysfunction, apathy, suicidal impulses, and mania—which may then lead patients to be diagnosed with and treated for bipolar disorder.

Indeed, Whitaker suspects that antidepressants—as well as Ritalin and other stimulants prescribed for attention-deficit disorder—have catalyzed the recent spike in bipolar disorder. Though bipolar disorder was relatively rare just a half-century ago, reported rates of it have increased more than a hundredfold, to one in 40 adults. Side effects attributed to lithium and other common medications for bipolar disorder include deficits in memory, learning ability, and fine-motor skills. Similarly, benzodiazepines such as Valium and Xanax, which are prescribed for anxiety, are addictive; withdrawal from these sedatives can cause effects ranging from insomnia to seizures, as well as panic attacks.

Whitaker’s analysis of treatments for schizophrenia is especially disturbing. Antipsychotics, from Thorazine to successors like Zyprexa, cause weight gain, physical tremors (called tardive dyskinesia) and, according to some studies, cognitive decline and brain shrinkage. Before the introduction of Thorazine in the 1950s, Whitaker asserts, almost two-thirds of the patients hospitalized for an initial episode of schizophrenia were released within a year, and most of this group did not require subsequent hospitalization.

Over the past half-century, the rate of schizophrenia-related disability has grown by a factor of four, and schizophrenia has come to be seen as a largely chronic, degenerative disease. A decades-long study by the World Health Organization found that schizophrenic patients fared better in poor nations, such as Nigeria and India, where antipsychotics are sparingly prescribed, than in wealthier regions such as the United States and Europe.

A long-term study by Martin Harrow, a psychologist at the University of Illinois College of Medicine, found an inverse correlation between medication for schizophrenia and positive, long-term outcomes. Beginning in the 1970s, Harrow tracked a group of 64 newly diagnosed schizophrenics. Forty percent of the nonmedicated patients recovered—meaning that they could become self-supporting—versus 5 percent of those who were medicated. Harrow theorized that those who were heavily medicated were sicker to begin with, but Whitaker suggests that the medications may be making some patients sicker.

Several possible objections to Whitaker’s case against psychiatry come to mind. First of all, as Harrow speculates, over time heavily medicated patients may not fare as well as less-medicated patients because the former truly are sicker. Also, the recent surge in mental disability may stem, at least in part, from a decrease in the stigma associated with mental illness, spurring more people to seek and obtain treatment and government assistance. In her review, Marcia Angell called Whitaker’s book “suggestive, if not conclusive,” which seems right to me. At the very least, Whitaker’s claims warrant further investigation.

Between 1985 and 2008, sales of antidepressants and antipsychotics multiplied almost fiftyfold, to $24.2-billion.

Although Whitaker doesn’t address electroconvulsive therapy, its persistence strikes me as yet another symptom of the weakness of modern psychiatry. It fell out of favor in the 1970s, in part because of its negative portrayal in the 1975 film One Flew Over the Cuckoo’s Nest, and yet about 100,000 Americans a year still receive ECT. Studies suggest that the therapy can provide temporary relief from acute depression, but virtually everyone who receives electroconvulsive therapy relapses within a year without further treatment. Proponents claim that ECT has few significant side effects, but this year an FDA panel ruled that ECT should remain classified as a “high-risk” procedure because it can cause persistent memory loss and other side effects. If SSRI’s and other psychiatric medications were truly effective, ECT would long ago have been tossed into the dustbin of failed psychiatric treatments.

So what happened to Phil’s son? When Phil called me, I told him that if my son were suicidally depressed, I’d resist giving him shock treatment unless doctors convinced me there was absolutely no alternative. Phil decided against ECT, and his son, after being released from the hospital, gradually stopped taking antidepressants too. He still struggles with depression, and he smokes more marijuana than Phil would like. But he is healthy enough to be starting college this fall.

http://chronicle.com/article/Are-Psychiatric-Medications/128976/

« Return to news items


Share

Mental health services have become increasingly dominated by psychiatry’s ”medical model”

Friday, September 16th, 2011

The Sydney Morning Herald, Australia – “With More Talk in Mind” – Sep 15, 2011

by Dr. John Reed, Professor of Clinical Psychology

SERIOUS problems in Victoria’s mental health system have been revealed recently in The Age. The important thing now is to find solutions. In doing so we should remember that although Victoria is in the spotlight, similar ”crises” occur regularly all over the world. Perhaps this is because Victoria is not alone in having a system based on fundamentally flawed principles.

Mental health services have become increasingly dominated by psychiatry’s ”medical model”, which claims that feeling depressed, anxious or paranoid is primarily caused by genetic predispositions and chemical imbalances.

This has led to alarming rises in chemical solutions to distress. In New Zealand, one in nine adults (and one in five women) is prescribed antidepressants every year.

The public, however, in every country studied, including Australia, believes that mental health problems are caused by issues such as stress, poverty and isolation. The public also prefers talking therapies to drugs and electroconvulsive therapy (ECT).

Research suggests the public is right. For example, the single best predictor of just about every mental health problem is poverty, followed by other social factors such as abuse, neglect and early loss of parents in childhood, and – once in adulthood – loneliness and a range of adverse events including losses and defeats of various kinds.

Meanwhile, reviews of studies on anti-depressants (which only recently have been able to include those previously kept secret by drug companies) conclude that they are superior to placebos only for those at the extreme end of the ”most severe” group of depressed people. This represents less than 10 per cent of the people who are receiving these drugs.

A recent Cochrane review (the type most highly regarded in the scientific community) for risperidone, a leading anti-psychotic drug, ”suggests that there is no clear difference between risperidone and [a] placebo”.

A placebo (from the Latin meaning ”I please”) is not necessarily a bad thing. Indeed the talking therapies are effective partly because, if done well, they too instil hope and expectations of recovery.

The problem is that psychiatric drugs often have serious adverse effects. Anti-psychotics, for instance, can cause rapid weight gain, loss of sexual function, diabetes, heart disease, neurodegeneration and reduced life span.

As previously reported, my review of ECT studies (with Professor Richard Bentall of Liverpool University) found that this treatment is ineffective for most recipients and frequently causes permanent memory loss. This in itself can be depressing.

ECT also has a slight but significant risk of death, most frequently from cardiovascular failure.

Inpatient units are equally ineffective and can also be damaging. When will we learn that putting large numbers of extremely distressed people in the same building is not a good idea?

What I conclude from all this is that any review of mental health services in Victoria, or anywhere else for that matter, should probably be led by anyone other than a psychiatrist – and certainly not in Victoria’s case the state’s Chief Psychiatrist, whose job, according to Dr Ruth Vine herself, is “to watch over how the system is functioning”.

It is unfair to expect Dr Vine to take an objective view on the failure of the system for which she is responsible. That lack of objectivity is amply demonstrated by her claims that ECT is “safe and effective” and that the problem is the public’s “negative” views.

Perhaps a lawyer from the Mental Health Legal Centre might be a good choice.

Read the rest of the article here: http://www.smh.com.au/opinion/society-and-culture/with-more-talk-in-mind-20110914-1k9m2.html#ixzz1Y8tVJQlv

 

« Return to news items


Share

Politics and mental health a poor mix

Wednesday, September 14th, 2011

The Sydney Morning Herald – September 13, 2011
by Tanveer Ahmed

"Mental health possesses a built-in capacity for abuse that is greater than in other areas of medicine."

Imagine a tribunal where the public could challenge clinical decisions by neurosurgeons or cardiologists. It would be ridiculous. But mental health is different. Unlike other medical specialties, it resembles law or politics: fields where subtle variations in the interpretation of a word can alter the entire trajectory of a patient’s treatment.

That’s why the right to appeal clinical decisions by mental health professionals through a tribunal, announced recently by the NSW government, met with public approval. Mental health possesses a built-in capacity for abuse that is greater than in other areas of medicine. A patient’s psychiatric diagnosis has enormous cultural power in many other fields, from the marketing of antidepressant medications, to general practice, disability claims and legal proceedings.

The contestable nature of mental health is also why there is a constant battle to keep it free from politics. Some of the 20th century’s most despotic regimes used mental health to oppress opponents, coining disorders such as ”delusions of capitalism” in the Soviet Union or ”politically paranoid” in China. But psychiatry has a way of becoming a political football in public discourse regardless of how authoritarian or democratic the society.

Today it is increasingly a tool of progressive politics, used to highlight the human pain apparently caused by harsh policies. In the case of asylum seekers, for example, any emotional distress is automatically viewed through the lens of mental health. Resilient individuals who have escaped harsh circumstances and coped with far-reaching travel are suddenly classified as fragile, undone by bureaucratic delay and limited incarceration. There is no doubt mental illness exists among asylum seekers, but its prevalence is vastly overstated.

In one of the more farcical applications of psychiatry to political debates, a report this month linked inaction on climate change to the possibility of worsening mental health. Released by the Climate Institute, it suggested that increasing natural disasters might be linked to climate change, which might lead to increased costs in mental healthcare. The evidence for every link was slight at best, yet the novelty of the report ensured widespread attention.

It was launched by Professor Ian Hickie, who has been rightly recognised for giving mental health a greater profile, but who has also played politics to do so.

Hickie has done more than any other clinician to promote tick-a-box diagnosis, particularly among general practitioners, who now regularly prescribe antidepressants through questionnaires alone.

"It is disingenuous to suggest, as McGorry has done, that there is no conflict of interest because their organisations are non-profit."

With former Australian of the Year Professor Patrick McGorry, Hickie has made overblown claims about the prevalence of mental health. It is disingenuous to suggest, as McGorry has done, that there is no conflict of interest because their organisations are non-profit. Their bodies shared in $2.2 billion of funding in the federal budget. Their exorbitant claims – such as one in four people will suffer mental illness – are indicative of a blurring of the lines between illness and normal, human responses to adversity.

Another good example of the uneasy relationship between politics and mental health – and how one can colour the other – is the former Victorian premier Jeff Kennett, a tireless campaigner in raising awareness for depression who openly admits he uses the term not in its medical context, but as a synonym for emotional distress.

The fiercest critics of this modern therapeutic culture in Western societies have argued that the decline of the political left is at the heart of the trend – in particular, the collapse of any ambition for social change.

Having given up on the notion that human beings could collectively change the world, the argument goes, the left has instead focused on people adapting to their circumstances.

« Return to news items


Share

Depression? Don’t believe it —Big Pharma has gained an ever greater hold over our mental & emotional lives

Friday, September 9th, 2011

The Brisbane Times, Australia – Spetember 9, 2011
by Lisa Appignanesi

"Over the last 40 years the Diagnostic and Statistical Manual of Mental Disorders - the bible of the psychiatric professions - has spawned more and more diagnostic categories, "inventing" disorders along the way and radically reducing the range of what can be construed as normal or sane. Meanwhile Big Pharma, feeding its appetite for profits and ours for drugs, has gained an ever greater hold over our mental and emotional lives, medicalising normality."

In 2000 the World Health Organisation named depression as the fourth leading contributor to the global burden of disease and predicted that by 2020 it would rise to second place. I suppose WHO didn’t mean it to sound like a target to be aimed for, but we seem to be rising to the challenge in any case.

A new survey from the European College of Psychopharmacology, a meta-analysis of a mass of research, reports that a staggering 164.8 million Europeans – 38.2 per cent of the population – suffer from a mental disorder in any year.

As well as depression, this includes neural disorders such as dementia and Parkinson’s; childhood problems from ADHD to “conduct disorder”; and the leading anxiety disorders – everything from panic attacks to obsessive-compulsive disorder to shyness. The latest figures for Australia, from 2007, indicate that more than one in five people – 3.2 million – had suffered from anxiety, a mood disorder or substance abuse in the preceding 12 months; 2-3 per cent more were estimated to have been affected by other mental illnesses.

Depression and anxiety, they tell us, are disproportionately women’s ailments. Men, it seems, become alcoholics (another illness category) rather than depressives, particularly in eastern Europe.

Such reports are worrying. They may draw attention to a rising toll of human suffering, but they pinpoint the imperialising tendency of the mental health sector. Our ills and unhappiness are squeezed into a package labelled “disorder” and an ever-proliferating assortment of supposedly objective diagnostic categories. A cure is somehow promised, though it rarely seems to come, certainly not for everyone or for ever. In talking to the press or drafting press releases, researchers often extrapolate from their material in order to create good copy.

The notion that women are somehow more prone to mental illness often emerges. According to Hans-Ulrich Wittchen, one of the report’s authors, the reason women suffer nearly twice as much depression and anxiety disorders as men lies in the changing social pattern in which women take on work on top of marriage and children.

So stay home, ladies, and you’ll be as happy as apple pie; though in the 50s when we stayed home to bake it, the doctors gave us Miltown and Valium to help us take pain-free care of hubby and the young ones.

On the subject of women’s greater susceptibility, it’s just as well to remember that women go to doctors far more than men, for all kinds of ills: indeed, women’s greater incidence of mental ills just about equals their greater number of visits to the doctors. If men went to doctors as often as they go to the pub, it’s a fair guess that their unhappiness would be represented as depression or anxiety as well.

One of the many things that became clear to me as I was working on my book on the rise and rise of the mind-doctoring professions over the last 200 years, is that classifications of mental disorder are hardly absolutes. They are far more often constructs that mirror their time’s aspirations and ways of understanding. They may reflect subjective experience, but only insofar as we can prod and organise our inchoate inner lives to fit pre-existing psychiatric tick lists.

Useful tools for statisticians, the classifications are also useful to public health administrators, insurance companies, lobbying bodies, or pharmaceutical companies who need “homogeneous populations” on whom to carry out drug trials. But I remain to be convinced that these proliferating classifications help individuals find relief – except, of course, that momentary relief from giving an expert name to what may feel like an intractable set of problems.

Over the last 40 years the Diagnostic and Statistical Manual of Mental Disorders – the bible of the psychiatric professions – has spawned more and more diagnostic categories, “inventing” disorders along the way and radically reducing the range of what can be construed as normal or sane. Meanwhile Big Pharma, feeding its appetite for profits and ours for drugs, has gained an ever greater hold over our mental and emotional lives, medicalising normality.

The more studies that come along to tell us about the rise in mental illness, the more we fit our problems and unhappiness into a category of mental disorder, developing symptoms to take to the doctor in search of a cure. Humans are suggestible creatures. And doctors like to help: they provide the pills Big Pharma recommends, though many must now know that research has shown placebos can work just as well and with fewer side effects.

If doctors – rather than politicians or teachers or priests or friends and family – are to be the guardians of our wellbeing, then doctors really should be provided with new kinds of “treatments”. Psycho- and group therapy could, of course, be rolled out, and not just of the 10-week variety: anything that builds up the individual’s inner resources and allows emotions to be reflected on can’t be bad.

But doctors could recommend group running for depression, proved to have far better effects than SSRIs. Reading groups, too, offer a definite lift. As for women, more free childcare, after-school clubs and husbands who take days off to go to the doctor with the kids (or sort out that drinking problem) would lift a depressed mood wonderfully. Then there’s poverty, terrible schools … could health systems take those on as well?

« Return to news items


Share

Australian MP Claims 1 in 5 Federal Politicians Taking Antidepressants

Thursday, September 8th, 2011

One in five politicians is on medication for depression, claims Andrew Robb

The Australian – September 8, 2011

by Michael Owen

LIBERAL frontbencher Andrew Robb claims 20 per cent of those in federal parliament are using antidepressants.

The opposition finance spokesman, who suffers a form of depression, said yesterday in Adelaide the high pressure of political life caused depressive illnesses.

“I do know that at least 20 per cent of the parliament are taking some sort of antidepressant medication,” he said. “I don’t know who they are, but I know they are. I certainly think for people who are under a lot of stress, like politicians or senior ministers, a lot thrive on that. But others who get a lot of stress, well that can cause a depressive condition.”

Mr Robb made the comments at the South Australian Press Club, where he spoke and answered questions about the challenges of managing depression and life in the Liberal Party.

read the rest of the article here: http://www.theaustralian.com.au/national-affairs/one-in-five-politicians-is-on-medication-for-depression-claims-andrew-robb/story-fn59niix-1226131720288

« Return to news items


Share

How Did These Babies Die? Question unites grieving families

Tuesday, August 2nd, 2011
BC LocalNews.com – August 1, 2011
by Jeremy Deutsch

Matthew Schultz was only 2.5 hours old when he died on Feb. 21, 2009. A coroner’s report stated there was no anatomical or toxicological cause of death, which was deemed “natural”. Another baby, Greyson Rawkins, was only two months old when he died on March 23 of this year. A coroner’s report found Greyson died of sudden unexplained death in infancy and his death was ruled undetermined. However, the mothers of both babies were taking Effexor while carrying and believe the antidepressant drug may be connected to the deaths of their children. And, as KTW learned, there are widespread medical warnings about pregnant women taking antidepressants.

Two hours is not a lot of time, but for little Matthew Schultz, it was his entire life.

One moment, Amery Schultz held Matthew in his arms. The next moment, his child was dead.

As the Merritt family struggled to deal with their grief, two years later and 45 minutes away in Kamloops, another family would be shattered by the sudden loss of a newborn.

Greyson Maxwell Rawkins was found one morning by his mother, cold and unresponsive.

The two-month old was dead.

Unlike most sudden-infant deaths, which go largely unexplained, both families believe they know exactly what killed their sons — an antidepressant called Effexor.

Matthew was born on February 21, 2009, at 2:21 a.m. at Royal Inland Hospital.

Right from birth, the newborn had poor colouring  and trouble breathing.

Schultz said he and wife Christiane argued with medical staff at the hospital about Matthew’s symptoms, only to be told they was normal.

An hour later, alone in the hospital room, Amery held Matthew in his arms.

He was gently rocking his fifth child to sleep and noted the baby’s lips were a bit purple.

Matthew fell asleep in his father’s lap.

Moments later, a nurse came into the room and noticed the new born was pale and unresponsive.

Matthew was in complete respiratory and cardiac arrest.

Medical staff were unable to revive him and he was pronounced dead an hour later.

“Losing your child — you can’t explain it,” Amery said.

“It tears a hole in your heart that will never heal.”

The B.C. Coroners Service listed Matthew’s death as natural — as far as the coroner was concerned, it was a case of sudden infant death syndrome (SIDS).

However, the Schultzes were not convinced.

The couple started to do their own research and were dismayed by what they found.

Christiane had been taking the antidepressant Effexor, also known by its clinical name venlafaxine, for years prior to Matthew’s birth and during pregnancy.

Three previous children were also exposed to the drug.

Unbeknownst to the couple, venlafaxine had been under a Health Canada warning since 2004.

The government agency had advised that newborns may be adversely affected when pregnant women take a specific group of antidepressants during the third trimester of pregnancy.

The list included venlafaxine.

The Schultzes said their family doctor never told them about the possible risks of taking the drug during pregnancy.

“I asked every pregnancy, ‘Should I get off of these?’” Christiane said.

“But I was told, ‘No, they’re fine, they’re perfectly safe.’”

Convinced Effexor contributed to Matthew’s death, the family awaited the final report from the coroner, hoping to get some answers as to the cause of their son’s death.

They were also hoping the coroner would make recommendations so other families wouldn’t suffer through a similar loss.

But the report, which the Schultzes received on the two-year anniversary of Matthew’s short life and death, surprised and angered the family.

It made no recommendations and found no cause of death.

According to the coroner’s report, a detailed autopsy on Matthew showed no anatomic cause of death, but the possibility was raised of venlafaxine exposure being a contributing factor.

Brain-tissue samples were sent to a research facility in the U.S. for examination to determine if there was an underlying susceptibility to the class of antidepressants.

But the report noted it was unclear how prenatal exposure to Effexor might have contributed to Matthew’s death, if at all.

The report concluded the significance of the exposure to venlafaxine in utero is unknown and made no recommendations.

“At best, I can’t bring my son back,” Amery said.

“But to call his death natural, certainly it’s not.”

He argued the coroners office has ignored what he considers overwhelming evidence the drug played a role in his son’s death.

The report itself listed exposure to venlafaxine under the category of other conditions contributing to death.

Physician and coroner Karla Pederson, with the B.C. Coroner’s Service, looked over the results of the report and is satisfied the office went to great lengths to find the cause of death.

“We are not making a presumption that we know what caused the death of this child, because we do not know,” she said.

When asked if the coroners service is concerned about the use of antidepressants during pregnancy, Pederson noted the drugs are used by thousands, if not millions, of pregnant women around the world without resulting in infant death.

Greyson Rawkins was born on Jan. 24, 2011, at RIH.

Like Matthew Schultz, little Greyson had trouble breathing at birth and spent five days in the hospital before he could go home for the first time.

“He was just different from my first,” said Greyson’s mother, Nicole Rawkins, who noted her second child weighed less and slept much more than her daughter, Layla, now three years old.

During her entire pregnancy, Rawkins said she was taking a prescribed 450-milligram daily dose of Effexor to help her depression.

It was more than five times the amount she took during her first pregnancy.

The 31-year-old Rawkins was also taking another drug called Seroquel, between 100 and 150 milligrams a day, which is used to treat bipolar depression.

She said her doctor never told her of the risks.

After two months, though, Greyson appeared to be doing well.

That was until the evening of March 22 of this year.

Rawkins put Greyson to sleep in his bassinet, in the same room with her and her boyfriend.

But the two-month old was being fussy, so mom brought him into her bed for nursing.

They fell asleep, with Greyson lying on the edge of the bed with his mom.

At around 4 a.m., Greyson’s older sister decided to climb into bed, while Rawkins’ boyfriend moved to a couch.

Five hours later, Rawkins awoke to find her son cold and unresponsive.

“I shook him a bit, but he was floppy,” she recalled.

Emergency services was dispatched, but it was too late.

Greyson was dead.

Rawkins thought she had accidently killed her baby, but that wasn’t the case.

A coroner’s report released at the end of June listed the death as undetermined and classified it as SIDS.

As in the Schultzes’ case, the autopsy noted Effexor and Seroquel as risk factors for SIDS in the case, but added it could not be determined by a pathological exam.

An autopsy on Greyson also stated the respiratory complications at birth were considered likely secondary to withdrawal effects from utero exposure to venlafaxine.

Despite the findings, Rawkins said the blame in Greyson’s death has fallen on her shoulders.

“I wasn’t allowed to grieve because everyone was watching me,” she said.

After getting in contact with the Schultz family and sharing their stories, Rawkins is also certain the antidepressants she had taken for months played a role in Greyson’s death.

The two mothers have been carrying around their own guilt because they unwittingly exposed their children to the drug.

“Every day I look at them and I did that to them because I didn’t look up the safety of the drug,” said Christiane.

“Every day is guilt.”

http://www.bclocalnews.com/news/126547313.html

« Return to news items


Share

America conned: Psycho pharma drug pushing empire under fire

Tuesday, July 26th, 2011

NaturalNews – July 26, 2011

by Monica G. Young

"psychopharma is looking like an idea whose time has passed."

Is America truly stricken with widespread mental illness? Do tens of millions need mind-altering drugs? A recent flurry of media articles lead readers to a realization that Big Pharma and the “mental health” industry have deceived Americans on a grand scale.

The “New York Review of Books” two-part article by Dr. Marcia Angell, Senior Lecturer at Harvard Medical School and former Editor in Chief of The New England Journal of Medicine, summarizes it extremely well. She analyzes three books by authors Irving Kirsch, Robert Whitaker, and Daniel Carlat. Each deconstructs the apparent mental illness epidemic and theory that mental disorders stem from brain chemical  imbalances which can be corrected by drugs.

Dr. Angell’s review has sparked a host of other journalists to applaud her and fuel the fire. An article in Forbes even concludes, “psychopharma is looking like an idea whose time has passed.”

As an overview:

Ten percent of Americans over age six take antidepressants. Antipsychotic drugs, once reserved for schizophrenics, have become the top-selling class of drugs in the US, with over $14 billion in sales in 2009. ADHD, bipolar and autism diagnoses have exploded in the past two decades with at least 5 million US kids now on psychiatric drugs.  Ten percent of boys take drugs for ADHD. Half a million kids take antipsychotics, including preschoolers.

The chemical imbalance theory rose to fame when Prozac hit the market in 1987, accompanied by massive hype that it corrected a chemical deficiency in the brain. In the years that followed, the number of people prescribed drugs for mental illness skyrocketed. Today, “treatment” for mental disorders is synonymous with psychoactive (mind-altering) drugs.

Tracing the origin of this theory shows it wasn’t that chemical imbalances were discovered in the mentally ill and then drugs were devised to correct the imbalance. Instead, drugs created for other purposes were incidentally found to also affect brain chemicals and blunt mental symptoms. Drug companies, hungry for new markets, and   psychiatry, eager to build stature in the medical arena, leapt on this. They conducted a vast campaign to popularize chemical imbalances as the cause of mental disturbance and push drugs as the answer.

As Dr. Angell writes, “instead of developing a drug to treat an abnormality, an abnormality was postulated to fit a drug.” “Or similarly,” she says, “one could argue that fevers are caused by too little aspirin.”

Many scientific studies disprove the chemical imbalance theory. After fifteen years of research, Irving Kirsch – psychologist and author of “The Emperor’s New Drugs” – concludes, “It now seems beyond question that the traditional account of depression as a chemical imbalance in the brain is simply wrong.” Research studies show psychoactive medications actually disrupt brain chemistry and causes the brain to function abnormally. This year prominent neuroscientist, Dr. Nancy Andreason, announced proof that antipsychotics shrink the brain.

Studies also demonstrate that long-term recovery rates are higher for nonmedicated patients. For instance, the World Health Organization conducted an investigation in fifteen cities around the world and out of 740 depressed individuals studied, those that weren’t on psychiatric drugs had the best long term outcomes.

In the pre-medication era, it was known that with time, people usually recovered from depression. If kids had tantrums, were unruly or shy, they were apt to outgrow it. Today, individuals branded with disorders are likely to receive long-lasting diagnoses, endless prescriptions and the poorer ones tend to remain on disability for life.

Big Pharma manipulation

Dr. Marcia Angell says the author of each of the three books agrees on “the disturbing extent to which the companies that sell psychoactive drugs – through various forms of marketing, both legal and illegal, and what many people would describe as bribery – have come to determine what constitutes a mental illness and how the disorders should be diagnosed and treated.”

According to IMS Health, an information and consulting company, pharmaceutical companies spent $6.1 billion in 2010 in marketing to US doctors. Another $4 billion was spent on direct-to-patient advertising.

Drug trials, used to bring a drug to market, are funded by drug companies, heavily biased and misleading. Companies may sponsor as many trials as they like until they have just two positive ones to submit to the FDA. Great care is taken to hide negative trials. The highly positive results of placebo trials are downplayed: a high percentage of patients recover on a fake drug (like a sugar pill) – proving that the more a person believes he will benefit from a treatment, the more likely he will experience a benefit.

In regards the Diagnostic and Statistical Manual – the psychiatric bible of mental disorders, used in prescribing drugs – Dr. Angell points out “in all of its editions, it has simply reflected the opinions of its writers.” The majority of the psychiatrists involved in creating the current edition had financial ties to drug companies.

Author Daniel Carlat points out that “psychiatrists consistently lead the pack of specialties when it comes to taking money from drug companies.”

Crime against humanity

And where has the “mental health” industry and “drug therapy” brought our nation?

As Americans line up at their local pharmacy, documented side effects are legion: weight gain, deadened emotions, diabetes, heart problems, liver damage, stunted growth in kids, shortened life spans and on and on. Those prescribed one psychoactive drug are commonly prescribed another to address side-effects, with many on daily cocktails of meds.

An estimated 2.2 million Americans are hospitalized each year for adverse drug reactions. Over 100,000 die from them.

Instead of decreasing, the number of adults on disability pay for mental illness has soared 250% since 1987 and for kids it’s a 35X increase.

The greatest  crime to humanity is the mass drugging of children. Yet it’s perpetrated within schools, doctors offices, foster homes and juvenile facilities daily.

There is good news. In the past few years, drug companies have faced a rise of multi-billion dollar class action suits. The key popularizer of childhood bipolar and antipsychotics for kids, Dr. Joseph Biederman, was publicly sanctioned by Harvard Medical School for failing to report $1.6 million he pocketed from drug companies. Some drugmakers are steering away from pursuing new psychoactive drugs.

Nazi chief propagandist Joseph Goebbels once said, “If you tell a lie big enough and keep repeating it, people will eventually come to believe it.”

This chemical-imbalance/drug therapy lie has been told big enough and repeated enough, that much of America believes it. Isn’t it time we all put a stop to it?

« Return to news items


Share

Battling over happy pills

Tuesday, July 26th, 2011

The Boston Globe – July 26, 2011

by Alex Beam

A scholarly tug of war over treating mental disorders boils down to one question: Do antidepressants work?

In this corner: Dr. Marcia Angell, former editor in chief of the New England Journal of Medicine, senior lecturer in social medicine at Harvard Medical School, and frequent critic of the pharmaceutical industry. In the opposite corner: Dr. Peter Kramer, Brown University psychiatry professor and author of the mega-selling “Listening to Prozac,’’ a book that helped convince thousands of Americans to live better, chemically.

At issue: a two-part article by Angell, published in The New York Review of Books, that assails psychiatrists and their pharmaceutical helpmeets, mainly antidepressants, on several fronts.

Item: Angell, quoting, among others, Tufts University psychiatrist Dr. Daniel Carlat, attacks the widely held belief that depression and other mental disorders result from chemical imbalances in the brain.

Item: Citing the research of British psychologist Irving Kirsch, Angell writes that some of the most widely used antidepressants, including Prozac, Paxil, Zoloft, Celexa, and Effexor, performed only marginally better than placebos in Food and Drug Administration tests, a “clinically meaningless’’ result.

Item: Angell uses a book by journalist Robert Whitaker to suggest that newly minted antipsychotic drugs may be causing “an epidemic of brain dysfunction.’’

A few days after Angell’s essay appeared, Kramer published a lengthy essay, “In Defense of Antidepressants’’ in The New York Times. His key point: “Antidepressants work – ordinarily well, on a par with other medications doctors prescribe.’’ Kramer attacked Kirsch’s analysis of FDA drug trials, allowing that they can be “quick’’ and “sloppy,’’ and adding that the kinds of people who present themselves for drug research studies “are likely to be an odd bunch.’’

More convincingly, Kramer cited drug companies’ “maintenance studies,’’ in which patients successfully taking antidepressants switched to dummy pills. “If the drugs are acting as placebos,’’ Kramer wrote, “switching should do nothing.’’ But the drugs significantly reduced the odds of relapse. “These results, rarely referenced in the antidepressant-as-placebo literature, hardly suggest that the usefulness of the drugs is all in patients’ heads,’’ Kramer concluded.

What prompted Kramer to defend antidepressants? “I had never really come out and said that antidepressants work in ordinary ways for ordinary diseases,’’ he said. “Doctors work with these tools all the time. It’s true that these medications are imperfect, and we would all like them to be better, but we’ve all seen them work. You would have to start from a really suspicious stance to think that the whole enterprise is corrupt.’’

In an interview, Angell replied: “In his article, Kramer says it’s well established that antidepressants work for chronic and recurrent mild depression, but where is the evidence for that? That screams out for a reference. Should we believe it just because he says that?

“You can’t base judgments on anecdotes from clinical experience, because that can be very misleading,’’ Angell said. “I have faith in the evidence – in rigorous, randomized, double blind controlled clinical trials, and that’s the only way we can get at the facts. Medical history is filled with storytelling, and it is often wrong.’’

Whose side am I on? I’m biased. If there were a religion that combined the non-loony elements of Christian Science, Scientology, and Episcopalianism – a tall order, I know – I would sign right up. Psychoactive drugs frighten me. I embrace my dysphoria, although I am sensitive enough to realize that this isn’t a life strategy that works for everyone.

Also, I read Angell’s brilliant, anti-lawyer, anti-journalist book-diatribe, “Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case,’’ and loved it. I read Kramer’s “Listening to Prozac’’ and had trouble finding the handle.

So I appealed to Dr. Steven Hyman, former director of the National Institute of Mental Health, now a visiting scholar at the Broad Institute, for a second opinion. Angell cites some of Hyman’s work – incorrectly, he says – in her NYRB article, so I figured he would have read both her essay, and Kramer’s.

He had. Hyman didn’t have much to say about Kramer’s Times essay, other than to remark that it seemed a little hurried. He had read Angell’s article closely, and was quite familiar with Kirsch’s “Prozac as placebo’’ theories, and with Angell’s low opinion of pharmaceutical companies. “I agree with her that the marketing practices of the big pharmaceutical companies have been awful,’’ Hyman said. “But it’s a leap to say that mental illness is a pharmaceutical company invention.’’ http://www.boston.com/lifestyle/articles/2011/07/26/do_antidepressants_work/

Note from CCHR to Dr. Steven Hyman:  You’re actually correct in stating “it’s a leap to say that mental illness” [as it has been falsely pawned off on the public as a biological/medical condition] is a “pharmaceutical company invention.”  You’re right. It’s not.   Drug companies can’t vote mental disorders into existence, categorize behaviors or emotions as “disease” and then without a shred of medical/scientific evidence to support them as such – repackage these behaviors as “illness” and pawn them off on as unsuspecting public as disease.  Only psychiatry can do that.  Pharma simply funds psychiatry’s mass marketing campaigns.   For more information click here: http://www.cchrint.org/psychiatric-disorders/

 

« Return to news items


Share